These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28473042)

  • 21. [Peripheral neuropathy with monoclonal gammopathy].
    Meier T; Meyer M
    Schweiz Med Wochenschr; 1990 Mar; 120(12):417-25. PubMed ID: 2157280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal gammopathy and neuropathy.
    Notermans NC
    Curr Opin Neurol; 1996 Oct; 9(5):334-7. PubMed ID: 8894407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
    van de Donk NW; Palumbo A; Johnsen HE; Engelhardt M; Gay F; Gregersen H; Hajek R; Kleber M; Ludwig H; Morgan G; Musto P; Plesner T; Sezer O; Terpos E; Waage A; Zweegman S; Einsele H; Sonneveld P; Lokhorst HM;
    Haematologica; 2014 Jun; 99(6):984-96. PubMed ID: 24658815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging concepts in monoclonal gammopathy of undetermined significance.
    Freytes CO
    Bol Asoc Med P R; 2010; 102(4):43-6. PubMed ID: 21766546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraproteinemic neuropathy.
    Zivković SA; Lacomis D; Lentzsch S
    Leuk Lymphoma; 2009 Sep; 50(9):1422-33. PubMed ID: 19637090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
    Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
    Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
    Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
    Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
    [No Abstract]   [Full Text] [Related]  

  • 28. Monoclonal gammopathies of undetermined significance.
    Kyle RA; Rajkumar SV
    Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience.
    Matà S; Torricelli S; Barilaro A; Grippo A; Forleo P; Del Mastio M; Sorbi S
    J Neurol Sci; 2021 Apr; 423():117335. PubMed ID: 33647732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls.
    Rögnvaldsson S; Steingrímsson V; Turesson I; Björkholm M; Landgren O; Yngvi Kristinsson S
    Haematologica; 2020 Nov; 105(11):2679-2681. PubMed ID: 33131261
    [No Abstract]   [Full Text] [Related]  

  • 31. Paraproteinemias and Peripheral Nerve Disease.
    Leavell Y; Shin SC
    Clin Geriatr Med; 2021 May; 37(2):301-312. PubMed ID: 33858612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
    Go RS; Gundrum JD; Neuner JM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment.
    Oganesyan A; Gregory A; Malard F; Ghahramanyan N; Mohty M; Kazandjian D; Mekinian A; Hakobyan Y
    Front Immunol; 2022; 13():1045002. PubMed ID: 36505449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal gammopathy-associated peripheral neuropathies: Uncovering pearls and challenges.
    Gonçalves TAP; Donadel CD; Frezatti RSS; Garibaldi PMM; Calado RT; Marques Junior W; Tomaselli PJ
    J Peripher Nerv Syst; 2024 Jun; 29(2):161-172. PubMed ID: 38873841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Polyneuropathies and monoclonal gammopathies, so-called benign].
    Vallat JM; Jauberteau MO; Arbo-Oze-de-Morvil C; Tabaraud F
    Rev Prat; 1992 Jan; 42(1):43-5. PubMed ID: 1314413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance.
    Henry Gomez T; Holkova B; Noreika D; Del Fabbro E
    BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27317760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal proteins in neuropathy.
    Kyle RA
    Neurol Clin; 1992 Aug; 10(3):713-34. PubMed ID: 1323750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal gammopathy and rheumatic diseases.
    Raposo A; Peixoto D; Bogas M
    Acta Reumatol Port; 2014; 39(1):12-8. PubMed ID: 24811457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide.
    Bhattacharyya J; Mihara K; Takihara Y; Kimura A
    Ann Hematol; 2012 May; 91(5):797-799. PubMed ID: 21901341
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.